Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., have described a next-generation vaccination technology ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...

The United States led the world in developing the technology that beat the COVID-19 pandemic. Action from lawmakers may leave ...

Before joining Moderna, Cronin spent close to 20 years at Ogilvy, working within its global healthcare department in ...

Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...

In a legal battle between BioNTech and CureVac, the European Patent Office declared a patent owned by CureVac ...

CoV-2, has affected millions of people worldwide. Despite the virus’ primary target being the respiratory system, it has ...

As vaccine sentiment fluctuates and political scrutiny increases, Yale researchers weigh in on scientific transparency, ...

The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.

The shocking rise of aggressive cancers post-COVID-19 is prompting concerns from health experts about the long-term consequences of mRNA vaccines. One of the world's leading oncologists, Dr. Patrick ...

Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.

We recently published a list of 10 Stocks To Trade Without Tariffs And Interest Rate Fears. In this article, we are going to ...